http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 08:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+20/26787346.html si-local-file:///var/storage/secattach/20260720/26787346.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+20/26787346.html Mon, 20 Jul 2026 08:02:00 -0400 ENLV O.13813208 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+20/26787346.html si-local-file:///var/storage/secattach/20260720/26787346.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+20/26787346.html Mon, 20 Jul 2026 08:02:00 -0400 ENLV O.13813208 http://www.streetinsider.com/Corporate+News/FDA+grants+RMAT+designation+to+Enlivex%27s+Allocetra+for+knee+OA/26760107.html <p>Enlivex Ltd. (NASDAQ: ENLV) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its clinical-stage immunotherapy Allocetra™ for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older.</p><p>The FDA based the designation on clinical evidence from a completed Phase I/IIa trial, in which patients with primary age-related knee osteoarthritis treated with Allocetra™ showed statistically significant and clinically meaningful improvements in knee pain and physical function compared with placebo, with efficacy that was durable through at least six months.</p><p>RMAT designation makes a therapy potentially eligible for accelerated approval, priority review, http://www.streetinsider.com/Corporate+News/FDA+grants+RMAT+designation+to+Enlivex%27s+Allocetra+for+knee+OA/26760107.html Mon, 13 Jul 2026 08:01:06 -0400 ENLV http://www.streetinsider.com/FDA/FDA+grants+RMAT+designation+to+Enlivex%27s+Allocetra+for+knee+OA/26760107.html <p>Enlivex Ltd. (NASDAQ: ENLV) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its clinical-stage immunotherapy Allocetra™ for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older.</p><p>The FDA based the designation on clinical evidence from a completed Phase I/IIa trial, in which patients with primary age-related knee osteoarthritis treated with Allocetra™ showed statistically significant and clinically meaningful improvements in knee pain and physical function compared with placebo, with efficacy that was durable through at least six months.</p><p>RMAT designation makes a therapy potentially eligible for accelerated approval, priority review, http://www.streetinsider.com/FDA/FDA+grants+RMAT+designation+to+Enlivex%27s+Allocetra+for+knee+OA/26760107.html Mon, 13 Jul 2026 08:01:06 -0400 ENLV http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Press+Releases/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (&quot;Enlivex&quot; or the &quot;Company&quot;), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Globe+Newswire/Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26760078.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 ENLV O.13813208 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+13/26760090.html si-local-file:///var/storage/secattach/20260713/26760090.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+13/26760090.html Mon, 13 Jul 2026 08:00:00 -0400 ENLV O.13813208 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+13/26760090.html si-local-file:///var/storage/secattach/20260713/26760090.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+13/26760090.html Mon, 13 Jul 2026 08:00:00 -0400 ENLV O.13813208 http://www.streetinsider.com/Press+Releases/+Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26759976.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Press+Releases/+Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26759976.html Mon, 13 Jul 2026 08:00:00 -0400 ENLV http://www.streetinsider.com/Globe+Newswire/+Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26759976.html <ul><li>FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.</li><li>RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval.</li></ul> <p>Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative http://www.streetinsider.com/Globe+Newswire/+Enlivex+Receives+FDA+Regenerative+Medicine+Advanced+Therapy+%28RMAT%29+Designation+for+Allocetra%E2%84%A2+in+Age-Related+Knee+Osteoarthritis/26759976.html Mon, 13 Jul 2026 08:00:00 -0400 ENLV http://www.streetinsider.com/Investing/Exclusive%3A+FDA+grants+RMAT+designation+to+Enlivex%E2%80%99s+Allocetra+for+knee+OA/26759638.html <p>Investing.com -- The FDA has granted Regenerative Medicine Advanced Therapy designation to Enlivex&amp;#39;s experimental immunotherapy Allocetra for age-related knee osteoarthritis, Investing.com has learned.</p> <p></p> <p dir="ltr">The designation applies to Allocetra&amp;#39;s use in patients aged 64 and older with symptomatic knee osteoarthritis, and is expected to give the biotech company more frequent, early-stage access to the FDA as it moves the therapy through its Phase IIb trial. </p> <p dir="ltr">RMAT status can also open the door to accelerated approval and priority review, potentially shortening the path to market.</p> <p dir="ltr">The designation is said to reflect confidence in data from Enlivex&amp;#39;s completed Phase I/IIa trial, in which patients with http://www.streetinsider.com/Investing/Exclusive%3A+FDA+grants+RMAT+designation+to+Enlivex%E2%80%99s+Allocetra+for+knee+OA/26759638.html Mon, 13 Jul 2026 07:06:46 -0400 ENLV http://www.streetinsider.com/General+News/Exclusive%3A+FDA+grants+RMAT+designation+to+Enlivex%E2%80%99s+Allocetra+for+knee+OA/26759638.html <p>Investing.com -- The FDA has granted Regenerative Medicine Advanced Therapy designation to Enlivex&amp;#39;s experimental immunotherapy Allocetra for age-related knee osteoarthritis, Investing.com has learned.</p> <p></p> <p dir="ltr">The designation applies to Allocetra&amp;#39;s use in patients aged 64 and older with symptomatic knee osteoarthritis, and is expected to give the biotech company more frequent, early-stage access to the FDA as it moves the therapy through its Phase IIb trial. </p> <p dir="ltr">RMAT status can also open the door to accelerated approval and priority review, potentially shortening the path to market.</p> <p dir="ltr">The designation is said to reflect confidence in data from Enlivex&amp;#39;s completed Phase I/IIa trial, in which patients with http://www.streetinsider.com/General+News/Exclusive%3A+FDA+grants+RMAT+designation+to+Enlivex%E2%80%99s+Allocetra+for+knee+OA/26759638.html Mon, 13 Jul 2026 07:06:46 -0400 ENLV http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+07/26738908.html si-local-file:///var/storage/secattach/20260707/26738908.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+07/26738908.html Tue, 07 Jul 2026 08:02:00 -0400 ENLV O.13813208 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+07/26738908.html si-local-file:///var/storage/secattach/20260707/26738908.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jul+07/26738908.html Tue, 07 Jul 2026 08:02:00 -0400 ENLV O.13813208 http://www.streetinsider.com/Stock+Splits/Enlivex+sets+1-for-15+reverse+stock+split+effective+July+9/26738824.html <p>Enlivex Ltd. (NASDAQ: ENLV) announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026, when shares will begin trading on the Nasdaq Capital Market on a split-adjusted basis.</p> <p>Under the terms of the reverse split, every 15 ordinary shares will be combined into one ordinary share. The number of issued and outstanding shares will decrease from 252,480,222 to approximately 16,832,015, subject to adjustments for fractional shares.</p> <p>The number of authorized ordinary shares will be reduced from 2,375,000,000 to 158,333,334, and the par value per share will increase from NIS 0.40 to NIS 6.00. Fractional shares will not be http://www.streetinsider.com/Stock+Splits/Enlivex+sets+1-for-15+reverse+stock+split+effective+July+9/26738824.html Tue, 07 Jul 2026 08:00:41 -0400 ENLV http://www.streetinsider.com/Press+Releases/Enlivex+Announces+1-for-15+Reverse+Stock+Split+Effective+July+9%2C+2026/26738704.html <p>Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split") of its ordinary shares. Beginning on July 9, 2026, the Company’s ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis.</p> <p>As a result of the Reverse Stock Split, every fifteen ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares will be ratably reduced from 2,375,000,000 to 158,333,334, and the par http://www.streetinsider.com/Press+Releases/Enlivex+Announces+1-for-15+Reverse+Stock+Split+Effective+July+9%2C+2026/26738704.html Tue, 07 Jul 2026 08:00:00 -0400 ENLV http://www.streetinsider.com/Globe+Newswire/Enlivex+Announces+1-for-15+Reverse+Stock+Split+Effective+July+9%2C+2026/26738704.html <p>Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split") of its ordinary shares. Beginning on July 9, 2026, the Company’s ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis.</p> <p>As a result of the Reverse Stock Split, every fifteen ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares will be ratably reduced from 2,375,000,000 to 158,333,334, and the par http://www.streetinsider.com/Globe+Newswire/Enlivex+Announces+1-for-15+Reverse+Stock+Split+Effective+July+9%2C+2026/26738704.html Tue, 07 Jul 2026 08:00:00 -0400 ENLV http://www.streetinsider.com/Corporate+News/Enlivex+RAIN+token+listed+on+Gate+cryptocurrency+exchange/26682447.html <p>Enlivex Ltd. (NASDAQ: ENLV) announced that its primary treasury asset, the RAIN token, was listed on the Gate cryptocurrency exchange on June 24, 2026, at 10:00 AM UTC.</p><p>Gate, founded in 2013, claims to serve over 54 million users globally and ranks among the top three digital asset exchanges worldwide by trading volume. The exchange holds what it describes as the second-largest 24-hour spot trading volume globally and supports trading for over 4,600 cryptocurrencies.</p><p>"Gate is one of the most established and widely accessed cryptocurrency exchanges in the world," said Oren Hershkovitz, CEO of Enlivex. "Exchange listings on platforms of this caliber http://www.streetinsider.com/Corporate+News/Enlivex+RAIN+token+listed+on+Gate+cryptocurrency+exchange/26682447.html Wed, 24 Jun 2026 08:02:19 -0400 ENLV http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jun+24/26682432.html si-local-file:///var/storage/secattach/20260624/26682432.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Enlivex+Ltd.++++++++++++++For%3A+Jun+24/26682432.html Wed, 24 Jun 2026 08:01:00 -0400 ENLV O.13813208